At the news
? NEUTRALIMPACT 3/10 S-3 filed Feb 24, 2026 at 16:10 ET
Myriad Genetics filed an S-3 shelf registration to potentially raise up to $200 million through future offerings of common stock, preferred stock, depositary shares, debt securities, or warrants. This is a routine capital markets tool, not an immediate offering, and provides flexibility for opportunistic fundraising. The company recently secured a $125 million term loan, indicating it has near-term liquidity but may seek additional capital for strategic needs.
- Myriad Genetics filed an S-3 shelf registration to register up to $200 million of securities.
- The filing allows for future offerings of common stock, preferred stock, depositary shares, debt securities, or warrants, either individually or in units.
- The shelf registration is a procedural step and does not mean an immediate offering is taking place.
- The company recently entered into a $125 million secured term loan in July 2025, which was used to repay its previous credit facility.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access